Conjugated To Proteinaceous Toxin Or Fragment Thereof (e.g., Conjugated To Diphtheria Toxin, Pseudomonas Exotoxin, Ricin, Gelonin, Abrin, Etc.) Patents (Class 424/183.1)
-
Patent number: 8216584Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.Type: GrantFiled: June 29, 2007Date of Patent: July 10, 2012Assignee: Cancer Research Technology LimitedInventors: Roy Bicknell, Lukasz Huminiecki
-
Patent number: 8211440Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.Type: GrantFiled: November 18, 2010Date of Patent: July 3, 2012Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20120156217Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: ApplicationFiled: October 28, 2011Publication date: June 21, 2012Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden
-
Publication number: 20120148600Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: November 28, 2011Publication date: June 14, 2012Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8198416Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.Type: GrantFiled: March 2, 2006Date of Patent: June 12, 2012Assignee: Universitaetsklinikum FreiburgInventors: Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
-
Publication number: 20120141372Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: ApplicationFiled: November 10, 2011Publication date: June 7, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20120141485Abstract: Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.Type: ApplicationFiled: December 1, 2011Publication date: June 7, 2012Inventors: Leon F. Garcia-Martinez, John A. Latham, Ethan W. Ojala, Corinne C. Akatsuka, Pei Fan, Jeffrey T.L. Smith, Benjamin H. Dutzar
-
Publication number: 20120141511Abstract: A novel agent for the targeted control of a mammalian cell activity can be used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E, linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain, which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome; Domain T is the Translocation Domain, which translocates the agent from within the endosome across the endosomal membrane into the cytosol of the cell; and Domain E is the Effector Domain, which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.Type: ApplicationFiled: October 11, 2011Publication date: June 7, 2012Inventors: Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
-
Publication number: 20120121504Abstract: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.Type: ApplicationFiled: May 12, 2010Publication date: May 17, 2012Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Svcs.Inventors: Christoph Rader, Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica M. Suschak
-
Publication number: 20120121591Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.Type: ApplicationFiled: March 19, 2010Publication date: May 17, 2012Applicant: Amgen Inc.Inventors: John K. Sullivan, Leslie P. Miranda, Colin V. Gegg, Shaw-Fen Sylvia Hu, Edward J. Belouski, Justin K. Murray, Hung Nguyen, Kenneth W. Walker, Taruna Arora, Frederick W. Jacobsen, Yue-Sheng Li, Thomas C. Boone
-
Publication number: 20120121503Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.Type: ApplicationFiled: November 12, 2010Publication date: May 17, 2012Applicants: National University Corporation Yamaguchi University, National University Corporation Chiba UniversityInventors: Toshinori Nakayama, Akihiro Hasegawa, Mutsunori Shirai
-
Publication number: 20120114556Abstract: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: IMMUNOMEDICS, INC.Inventors: David M. GOLDENBERG, Hans J. HANSEN
-
Publication number: 20120114704Abstract: The present invention provides antibodies or antigen-binding fragments thereof that specifically hind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.Type: ApplicationFiled: March 23, 2010Publication date: May 10, 2012Inventor: Elena Feinstein
-
Publication number: 20120100161Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.Type: ApplicationFiled: April 8, 2010Publication date: April 26, 2012Inventors: Heinz Faulstich, Gerhard Moldenhauer, Werner Simon, Jan Anderl, Christoph Müller
-
Patent number: 8158128Abstract: The present invention provides progastrin-binding molecules specific for progastrin that do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly), or glycine-extended gastrin-34(G34-Gly). Further, the invention provides monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin and the hybridomas that produce these MAbs. Also provided are panels of Mabs useful for the detection and quantitation of progastrin and gastrin hormone species in immuno-detection and quantitation assays. These assays are useful for diagnosing and monitoring a gastrin-promoted disease or condition, or for monitoring the progress of a course of therapy. The invention further provides solid phase assays including immunohistochemical (IHC) and immunofluorescence (IF) assays suitable for detection and visualization of gastrin species in solid samples, such as biopsy samples or tissue slices.Type: GrantFiled: September 21, 2005Date of Patent: April 17, 2012Assignee: Cancer Advances, Inc.Inventor: Stephen Grimes
-
Publication number: 20120052007Abstract: The invention provides SPARC binding antibodies that have high affinity to SPARC, particularly plasma SPARC, and methods of using such antibodies in treating conditions including cancer.Type: ApplicationFiled: June 3, 2011Publication date: March 1, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Vuong Trieu, Xiping Liu, Neil Desai
-
Patent number: 8124094Abstract: Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising such a complex. The Fc fragment modified by a non-peptide peptide according to the present invention lacks immunogenicity and effector functions. Due to these properties, the Fc fragment maintains the in vivo activity of a drug conjugated thereto in high levels, remarkably increases the serum half-life of the drug, and remarkably reduces the risk of inducing immune responses.Type: GrantFiled: April 28, 2005Date of Patent: February 28, 2012Assignee: Hanmi Holdings Co., Ltd.Inventors: Young Min Kim, Sung Min Bae, Dae Jin Kim, Dae Hae Song, Chang Ki Lim, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20120042416Abstract: The present invention relates to fusion proteins comprising anti-Oomycotic proteins or peptides linked to an antibody or fragment thereof specifically recognising an epitope of an Oomycota. The invention is also directed to polynucleotides coding for the fusion proteins. The embodiments of the present invention are particularly useful for the protection of plants against Oomycota. The invention therefore comprises transgenic plants expressing the fusion proteins of the present invention.Type: ApplicationFiled: August 5, 2010Publication date: February 16, 2012Applicant: Fraunhofer-Gesellschaft zur Forderung der angewandten e.V.Inventors: Sylvia Schleker, Dieter Peschen, Rainer Fischer, Stefan Schillberg
-
Publication number: 20120034223Abstract: The present disclosure relates to methods and uses of improving the therapeutic efficacy and utility of antibody fragments by employing anti-epitope-tagging technologies.Type: ApplicationFiled: November 6, 2009Publication date: February 9, 2012Inventors: Christopher J. Hall, Michael D. Mclean, Xuemei Xie, Nina Weisser, Kurt C. Almquist
-
Publication number: 20120027785Abstract: This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the invention provides methods, utilizing the recombinant polypeptide encoding the chimera, such as a method for inhibiting the proliferation of a neoplastic cell, a method for treating a neoplastic disease in a human subject, a method for inhibiting or suppressing a neoplastic disease in a human subject, and a method for reducing the symptoms associated with a neoplastic disease in a human subject.Type: ApplicationFiled: August 17, 2010Publication date: February 2, 2012Inventor: JOSEPH M. DIRIENZO
-
Patent number: 8105596Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: March 15, 2011Date of Patent: January 31, 2012Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Publication number: 20120020888Abstract: Described are bladder cancer specific biomarkers and lung cancer specific biomarkers comprising the nucleic acid sequence of the Engrailed-2 (EN2) gene or the amino acid sequence of the encoded EN2 protein. Also described are uses of the biomarkers in the treatment, diagnosis, monitoring and imaging of bladder cancer and lung cancer.Type: ApplicationFiled: December 21, 2009Publication date: January 26, 2012Applicant: THE UNIVERSITY OF SURREYInventors: Richard Morgan, Hardev S. Pandha
-
Patent number: 8092809Abstract: This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using these immunogens also are provided.Type: GrantFiled: December 20, 2007Date of Patent: January 10, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventor: David FitzGerald
-
Patent number: 8084029Abstract: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.Type: GrantFiled: April 20, 2011Date of Patent: December 27, 2011Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 8080250Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: GrantFiled: June 20, 2011Date of Patent: December 20, 2011Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Publication number: 20110305631Abstract: Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other.Type: ApplicationFiled: August 19, 2011Publication date: December 15, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20110300163Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.Type: ApplicationFiled: June 2, 2011Publication date: December 8, 2011Inventors: Brian Robert Champion, David Robert Stead, Paul Andrew Wright
-
Patent number: 8071093Abstract: Disclosed are fully human anti-epidermal growth factor receptor (EGFR) antibodies, fragments thereof, and nucleic acid sequences encoding for the same. Further disclosed are methods of making and using the antibodies.Type: GrantFiled: May 17, 2010Date of Patent: December 6, 2011Assignee: Samsung Electronics Co., Ltd.Inventors: Sang Won Seo, A Yeon Cho, Sung Young Jeong
-
Patent number: 8071096Abstract: The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.Type: GrantFiled: January 24, 2003Date of Patent: December 6, 2011Assignee: G2 Therapies LtdInventor: Charles Reay MacKay
-
Patent number: 8071072Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: May 30, 2007Date of Patent: December 6, 2011Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey, Maximiliano Vasquez
-
Publication number: 20110293639Abstract: In a method embodiment, a method includes introducing a plurality of Ideotypically Modulated Pharmacoeffectors (IMP) into a population of cells. Each IMP may include a detection domain and an activation domain. One or more epitopes is bound by the detection domain. The activation domain is activated in response to the binding. Applications may include but are not limited to viral infections, other intracellular infections, cancers, vector-borne diseases, autoimmune diseases, cellular diseases, cellular enhancement, and research.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Inventor: Jacob Orme
-
Publication number: 20110293512Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin ?v?6, and the responsiveness of patient populations to ?v?6-active compounds and compositions (e.g., antibodies and other ligands that bind ?v?6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas.Type: ApplicationFiled: April 18, 2011Publication date: December 1, 2011Applicant: BIOGEN IDEC MA INC.Inventors: Shelia M. Violette, Louise A. Koopman
-
Patent number: 8067007Abstract: Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach or esophageal cancer are disclosed.Type: GrantFiled: December 6, 2010Date of Patent: November 29, 2011Assignee: Thomas Jefferson UniversityInventors: Scott A. Waldman, Jason Park, Stephanie Schulz
-
Patent number: 8067546Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.Type: GrantFiled: April 19, 2006Date of Patent: November 29, 2011Assignee: Seattle Genetics, Inc.Inventors: Charlotte McDonagh, Paul Carter, Julie McEarchern, Che-Leung Law
-
Publication number: 20110280800Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.Type: ApplicationFiled: May 13, 2011Publication date: November 17, 2011Applicant: ABBOTT LABORATORIESInventors: Chengbin WU, Tariq GHAYUR, Chung-ming HSIEH, Dominic J. AMBROSI
-
Publication number: 20110280892Abstract: The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins.Type: ApplicationFiled: December 21, 2010Publication date: November 17, 2011Applicants: MedImmune, LLC, Seattle Genetics, Inc.Inventors: Michael S. Kinch, Herren Wu, Christine Bachy, David Tice, Changshou Gao, Peter D. Senter
-
Publication number: 20110262448Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided.Type: ApplicationFiled: September 29, 2008Publication date: October 27, 2011Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Jonathan A. TERRETT, Sarah L. Pogue, Kristopher Toy, Lan Yang, Chetana Rao-Naik, Bingliang Chen
-
Patent number: 8043621Abstract: The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.Type: GrantFiled: May 8, 2008Date of Patent: October 25, 2011Assignee: Ramot at Tel Aviv University Ltd.Inventors: Itai Benhar, Yariv Mazor
-
Patent number: 8039000Abstract: A novel gene (designated 158P3D2) and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.Type: GrantFiled: July 6, 2006Date of Patent: October 18, 2011Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Mary Faris, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Rene S. Hubert, Daniel E. H. Afar, Wangmao Ge, Arthur B. Raitano, Pia M. Challita-Eid
-
Publication number: 20110250130Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-?), e.g., human TNF-?, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: April 6, 2011Publication date: October 13, 2011Inventors: Lorenzo Benatuil, Tariq Ghayur, Carrie L. Goodreau, Peter C. Isakson, Jochen Salfeld
-
Patent number: 8034351Abstract: The present invention provides compositions and methods for augmenting vaccine immunogenicity using mucin-immunoglobulin fusion proteins.Type: GrantFiled: April 22, 2003Date of Patent: October 11, 2011Assignee: Recopharma ABInventor: Jan Holgersson
-
Publication number: 20110243841Abstract: Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.Type: ApplicationFiled: March 29, 2011Publication date: October 6, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8026209Abstract: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain barrier functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides herein. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain barrier properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.Type: GrantFiled: February 10, 2004Date of Patent: September 27, 2011Assignee: BBB Holding B.V.Inventors: Pieter Jaap Gaillard, Albertus Gerrit De Boer, Arjen Brink
-
Patent number: 8012485Abstract: The invention provides a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human the reconstituted composition such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.Type: GrantFiled: February 6, 2009Date of Patent: September 6, 2011Assignee: ImmunoGen, Inc.Inventors: Godfrey Amphlett, Wei Zhang, Michael Fleming
-
Patent number: 8013128Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: March 4, 2009Date of Patent: September 6, 2011Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Publication number: 20110212022Abstract: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.Type: ApplicationFiled: August 5, 2010Publication date: September 1, 2011Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Kenneth L. ROCK, Dancella FERNANDES
-
Publication number: 20110195019Abstract: A novel gene 251P5G2 and its encoded protein, and variants thereof, are described wherein 251P5G2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 251P5G2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 251P5G2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 251P5G2 can be used in active or passive immunization.Type: ApplicationFiled: December 31, 2009Publication date: August 11, 2011Applicant: AGENSYS, INC.Inventors: ARTHUR B. RAITANO, PIA M. CHALLITA-EID, AYA JAKOBOVITS, MARY FARIS, WANGMAO GE
-
Publication number: 20110195020Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: ApplicationFiled: February 4, 2011Publication date: August 11, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20110189209Abstract: Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.Type: ApplicationFiled: August 1, 2008Publication date: August 4, 2011Applicant: The Government of The United States of America as Represented by the Secretary, Dept. of HealthInventors: David M. Neville, JR., Jung-Hee Woo, Arthur Frankel
-
Patent number: 7985842Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: November 24, 2008Date of Patent: July 26, 2011Assignee: Immunogen Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian